[{"orgOrder":0,"company":"Avenacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Ampicillin","moa":"||PBP","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Inapplicable"},{"orgOrder":0,"company":"Sharp HealthCare","sponsor":"The University of Pittsburgh School of Medicine | Morgan Stanley Children\u2019s Hospital | University of Louisville | Sharp Mary Birch Hospital for Women & Newborns | Children's Hospital of Philadelphia | Jefferson Medical College of Thomas Jefferson Universi","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ampicillin","moa":"||Bacterial penicillin-binding protein","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Sharp HealthCare","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Sharp HealthCare \/ The University of Pittsburgh School of Medicine | Morgan Stanley Children\u2019s Hospital | University of Louisville | Sharp Mary Birch Hospital for Women & Newborns | Children's Hospital of Philadelphia | Jefferson Medical College of Thomas Jefferson Universi","highestDevelopmentStatusID":"10","companyTruncated":"Sharp HealthCare \/ The University of Pittsburgh School of Medicine | Morgan Stanley Children\u2019s Hospital | University of Louisville | Sharp Mary Birch Hospital for Women & Newborns | Children's Hospital of Philadelphia | Jefferson Medical College of Thomas Jefferson Universi"}]

Find Clinical Drug Pipeline Developments & Deals for ABPC

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Avenacy has launched a suite of antibiotic products for injection, including ampicillin, ampicillin and sulbactam, nafcillin, piperacillin and tazobactam.

                          Product Name : Omnipen-N-Generic

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          March 17, 2025

                          Lead Product(s) : Ampicillin,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Sharp HealthCare

                          Country arrow
                          EPSC
                          Not Confirmed

                          Sharp HealthCare

                          Country arrow
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Ampicillin,Gentamicin Sulfate

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Study Phase : Phase III

                          Sponsor : The University of Pittsburgh School of Medicine | Morgan Stanley Children’s Hospital | University of Louisville | Sharp Mary Birch Hospital for Women & Newborns | Children's Hospital of Philadelphia | Jefferson Medical College of Thomas Jefferson Universi

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          August 04, 2023

                          Lead Product(s) : Ampicillin,Gentamicin Sulfate

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase III

                          Sponsor : The University of Pittsburgh School of Medicine | Morgan Stanley Children’s Hospital | University of Louisville | Sharp Mary Birch Hospital for Women & Newborns | Children's Hospital of Philadelphia | Jefferson Medical College of Thomas Jefferson Universi

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 15, 2019

                          Lead Product(s) : Rosuvastatin Calcium,Ampicillin

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Mercy Health

                          Country arrow
                          EPSC
                          Not Confirmed

                          Mercy Health

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          June 18, 2018

                          Lead Product(s) : Cefazolin,Gentamicin Sulfate,Ceftriaxone,Ampicillin,Sulbactam,Piperacillin Sodium,Tazobactam Sodium

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Northwell Health

                          Country arrow
                          EPSC
                          Not Confirmed

                          Northwell Health

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          October 19, 2015

                          Lead Product(s) : Cephalosporin,Levofloxacin,Clindamycin Hydrochloride,Ampicillin,Gentamicin Sulfate

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 23, 2015

                          Lead Product(s) : Ceftaroline Fosamil,Ampicillin,Aminoglycoside

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : PRA Health Sciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Michael Cohen-Wolkowiez

                          Country arrow
                          EPSC
                          Not Confirmed

                          Michael Cohen-Wolkowiez

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          November 26, 2013

                          Lead Product(s) : Ampicillin,Metronidazole,Gentamicin Sulfate,Clindamycin Hydrochloride,Piperacillin Sodium,Tazobactam Sodium

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : The Emmes Company, LLC

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          University of Florida

                          Country arrow
                          EPSC
                          Not Confirmed

                          University of Florida

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          September 14, 2011

                          Lead Product(s) : Ampicillin,Inapplicable

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Tyler's Hope for a Dystonia Cure, Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank